QueueMar 1, 2017Latest in HomeWhole-body PET shows how naloxone blocks opioidsMay 9, 2025Komen rails against proposed federal cuts to women's health programMay 9, 2025CT muscle metrics could help screen for sarcopeniaMay 8, 2025Cancer incidence on rise in younger people, womenMay 8, 2025Related StoriesHome#MyRadGirlfriend No. 27: Good job on that caseHome#MyRadGirlfriend No. 26: Name on the bottleHome#MyRadGirlfriend No. 25: Texting while ...Home#MyRadGirlfriend No. 24: That thing's a carcinogen
![Images depict axial MRI scans in a 50-year-old premenopausal female patient with biopsy-proven 12-mm invasive lobular cancer in the lower outer quadrant of the left breast. Upper images are subtracted dynamic contrast-enhanced (DCE) MRI scans from the first and second postcontrast acquisitions. Lower images are ultrafast MRI scans obtained within 24 hours after the DCE study (four consecutive subtracted dynamic frames from time points [T] 6–9). There is marked background parenchymal enhancement (BPE) on the DCE MRI scans. Thus, the known cancer (arrow) is barely visible; it exhibits only slightly stronger enhancement than the normal fibroglandular tissue, which results in low conspicuity. At ultrafast MRI there is less BPE, and still the cancer is barely visible because it starts to enhance simultaneously with the BPE. The conspicuity of the cancer is even reduced compared with the DCE series. Both of the readers missed this cancer on both the DCE and ultrafast MRI scans.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2025/05/2025-05-06-rsna-ultrafast-dce-mri-breast.Gzvq76udFr.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
